Esophageal Disease
2
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Small Molecule
1100%
+ 1 programs with unclassified modality
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Dong-A STPantoprazole
Ildong PharmaceuticalRabeprazole 20mg bid
Clinical Trials (2)
Total enrollment: 143 patients across 2 trials
Efficacy of DA-5204 on Gastroesophageal Reflux Disease
Start: Jun 2016Est. completion: Dec 201870 patients
Phase 3Completed
Treatment Response of High-dose and Standard-dose Rabeprazole for Extra-esophageal Reflux.
Start: Oct 2012Est. completion: May 201473 patients
Phase 3Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 late-stage (Phase 3) programs, potential near-term approvals
Small Molecule is the dominant modality (100% of programs)
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.